StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Memantine Hydrochloride

HCID 181458
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
19982-08-2
Standard-SMILES
CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl
InChIKey
LDDHMLJTFXJGPI-UHFFFAOYSA-N
Summenformel
C12H22ClN
Durchschnittliche Molmasse
215,76 g/mol
Monoisotopische Masse
215,1440774

Überblick

Memantine hydrochloride is a hydrochloride obtained by reaction of memantine with one equivalent of hydrochloric acid. A low to moderate affinity uncompetitive (open-channel); NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. It has a role as an antidepressant, an antiparkinson drug, a dopaminergic agent, a NMDA receptor antagonist and a neuroprotective agent. It contains a memantinium(1+).

Namen und Bezeichner

Bevorzugter Name
Memantine Hydrochloride
IUPAC
3,5-dimethyladamantan-1-amine;hydrochloride
Englischer Name
Memantine
Summenformel
C12H21N
Molmasse
179.3

Namen und Synonyme

MEMANTINE HYDROCHLORIDE41100-52-1Memantine HCL3,5-dimethyladamantan-1-amine hydrochloride3,5-Dimethyl-1-adamantanamine hydrochlorideAkatinolNamenda XRMemaryMemantine MerzMemantine MylanMemantine AccordMemantine LEK
Weitere Namen anzeigen
C137361-Amino-3,5-dimethyladamantane(1r,3R,5S,7r)-3,5-dimethyladamantan-1-amineMEMANTINEMemartineAKOS BB-9600AURORA KA-7643Memantine(Base)7-DIMETHYLXANTHINETIMTEC-BB SBB002574
1-Amino-3,5-dimethyladamantane HydrochlorideAcrescentBalaxurAuxuraMemantine ratiopharmJY0WD0UA60SUN-Y7017NSC-102290

Datenbank-Bezeichner

CAS
19982-08-2、41100-52-1
PubChem CID
181458
DTXSID
DTXSID90961439

Eigenschaften

Berechnete Struktureigenschaften

Polarare Oberfläche (TPSA)
26 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
1
Frei drehbare Bindungen
0
Schwere Atome
14
Formalladung
0
Komplexität
240

Experimentelle und physikochemische Eigenschaften

Solubility29.4 [ug/mL] (The mean of the results at pH 7.4)
Human Drugs · 6 Einträge

Breast Feeding; Lactation; Milk, Human; Antiparkinson Agents; Dopamine Agents; Excitatory Amino Acid Antagonists

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

Collision Cross Section145.1 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
258 °C · 258 °C
Siedepunkt
239.8 · 239.8±8.0 °C(Predicted)
Dichte
1.046 · 1.046
Brechungsindex
25 · nD25 1.4941
storage temp.
2 · Keep in dark place,Inert atmosphere,2-8°C
Löslichkeit
Chloroform (Slightly), DMSO (Slightly)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 5 Einträge

This chemical does not meet GHS hazard criteria for 5% (1 of 20) of reports.

Warning

H302 (80%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 20 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 4 (80%)

Toxikologische Informationen

TreatmentAs in any cases of overdose, general supportive measures should be utilized, and treatment should be symptomatic. Elimination of memantine can be enhanced by acidification of urine. (L1712)
Exposure RoutesWell absorbed orally with a bioavailability of approximately 100%. Peak plasma concentrations are reached in 3-7 hours. Food has no effect on absorption.
Toxicity Summary · 1 Eintrag

Memantine exerts its action through uncompetitive NMDA receptor antagonism, binding preferentially to the NMDA receptor-operated cation channels. Prolonged increased levels of glutamate in the brain of demented patients are sufficient to counter the voltage-dependent block of NMDA receptors by Mg<sup>2+</sup> ions and allow continuous influx of Ca<sup>2+</sup> ions into cells, ultimately resulting in neuronal degeneration. Studies suggest that memantine binds more effectively than Mg<sup>2+</sup> ions at the NMDA receptor, and thereby effectively blocks this prolonged influx of Ca<sup>2+</sup> ions through the NMDA channel whilst preserving the transient physiological activation of the channels by higher concentrations of synaptically released glutamate. Thus memantine protects against chronically elevated concentrations of glutamate. Memantine also has antagonistic activity at the type 3 serotonergic (5-HT<sub>3</sub>) receptor with a potency that is similar to that at the NMDA receptor, and lower antagonistic activity at the nicotinic acetylcholine receptor. This drug has no affinity for gamma-aminobutyric acid (GABA), benzodiazepine, dopamine, adrenergic, histamine, or glycine receptors or for voltage-dependent calcium, sodium, or potassium channels.

Chemie und Industrie

Pharmakologische Informationen

Metabolism/Metabolites · 1 Eintrag

Excreted largely unchanged. About 20% is metabolized to 1-amino-3-hydroxymethyl-5-methyl-adamantane and 3-amino-1-hydroxy-5,7-dimethyl-adamantane. Route of Elimination: Memantine undergoes partial hepatic metabolism. About 48% of administered drug is excreted unchanged in urine; the remainder is converted primarily to three polar metabolites which possess minimal NMDA receptor antagonistic activity: the N-glucuronide conjugate, 6-hydroxy memantine, and 1-nitroso-deaminated memantine. It is excreted predominantly in the urine, unchanged. Half Life: 60-100 hours

FDA Pharmacological Classification · 6 Einträge

MEMANTINE HYDROCHLORIDE

NMDA Receptor Antagonists [MoA]; N-methyl-D-aspartate Receptor Antagonist [EPC]

MEMANTINE HYDROCHLORIDE ORAL

NMDA Receptor Antagonists [MoA]; N-methyl-D-aspartate Receptor Antagonist [EPC]

MEMANTINE HCL

NMDA Receptor Antagonists [MoA]; N-methyl-D-aspartate Receptor Antagonist [EPC]

MeSH Pharmacological Classification · 3 Einträge

Agents used in the treatment of Parkinson&apos;s disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.

Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.

Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists.

Verwendung und Herstellung

UsesFor the treatment of moderate to severe dementia of the Alzheimer's type.
Anwendungen · 2 Einträge

HistoryMemantine was first synthesized, patented, and described by Eli Lilly and Company in 1963 as an anti-diabetic agent, but it was ineffective at lowering blood sugar. By 1972, it was discovered to have central nervous system (CNS) activity, and was developed by Merz for treatment of neurological diseases, such as Parkinson's disease. Memantine was first studied in the treatment of Alzheimer's disease in 1986. The drug was first marketed for dementia in 1989 in Germany under the name Axura. Memantine was approved in the European Union in 2002 and in the United States in 2003.

Zugehörige Reaktionen

4
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 84161
HRID 84161als Edukt
Reaktionsgleichung von HRID 922821
HRID 922821als Edukt
Reaktionsgleichung von HRID 1112396
HRID 1112396als Produkt
Reaktionsgleichung von HRID 1783798
HRID 1783798als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
ChEMBL
CHEMBL1699
ChEBI
CHEBI:64323
UNII
JY0WD0UA60
EC Number
255-219-6
Aggregatzustand
Solid
pka
10.79 · 10.79±0.60(Predicted)
Farbe
Colorless Oil to Off-White Waxy
BCS Class
1 · 1
InChI
InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3
InChIKey
BUGYDGFZZOZRHP-UHFFFAOYSA-N
SMILES
C12(N)CC3(C)CC(CC(C)(C3)C1)C2
CAS Datenbank
19982 · 19982-08-2(CAS DataBase Reference)
Signs and Symptoms · 1 Eintrag

Side effects include pain, abnormal crying, leg pain, fever, increased apetite. Adverse drug reactions include: dizziness, confusion, headache, hallucinations, tiredness. Less common side effects include: vomiting, anxiety, hypertonia, cystitis, and increased libido. Doses of up to 400 mg have been tolerated.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Memantine hydrochloride

vLess-DILI-concern

7

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

hazard_code
Xi
safety_code
24/25
Giftige Stoffe Daten
19982-08-2(Hazardous Substances Data)

VerwendenRecent phase 3 clinical trials have shown that Memantine is an effective way of treatment of both mild and moderate-to-severe Alzheimer''s disease and possibly vascular dementia (multi-infarct dementia). Memantine’s method of action involves an uncompetitive, low-affinity, open-channel blocker; it enters the receptor-associated ion channel preferentially when it is excessively open, and, most importantly, its off-rate is relatively fast so that it does not substantially accumulate in the channel to interfere with normal synaptic transmission.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

SchwefelsureNatriumhydroxidHydrogenchloridAcetonitril
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: A primary aliphatic amine that is the 3,5-dimethyl derivative of 1-aminoadamantane. A low to moderate affinity uncompetitive (open-channel); NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels.